Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors

Hiromasa Tsuiki, Mehdi Tnani, Isamu Okamoto, Lawrence C. Kenyon, David R. Emlet, Marina Holgado-Madruga, Irene S. Lanham, Christopher J. Joynes, Kim T. Vo, Albert J. Wong

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

The c-Jun NH2-terminal kinases (JNKs) have a role both in promoting apoptosis and tumorigenesis. The JNKs are encoded by three separate genes (JNK1, 2, and 3), which are spliced alternatively to create 10 JNK isoforms that are either Mr 55,000 or 46,000 in size. However, the functional significance and distinct role for each splice variant remains unclear. We have noted previously that 86% of primary human glial tumors show activation of almost exclusively the Mr 55,000 isoforms of JNK. To further study which isoforms are involved, we constructed glutathione S-transferase fusion proteins for all 10 JNK isoforms and examined kinase activity with or without the activating upstream kinase. Surprisingly, five JNK isoforms demonstrate autophosphorylation activity, and in addition, all four JNK2 isoforms (either Mr 55,000 or 46,000) show a high basal level of substrate kinase activity in the absence of the upstream kinase, especially a Mr 55,000 JNK2 isoform. Examination revealed autophosphorylation activity at the T-P-Y motif, which is critical for JNK activation, because a mutant lacking the dual phosphorylation sites did not show autophosphorylation or basal kinase activity. Using green fluorescence protein-JNK expression vectors, transient transfection into U87MG cells demonstrates that although the JNK1 isoforms localize predominantly to the cytoplasm, the JNK2 isoforms localize to the nucleus and are phosphorylated, confirming the constitutive activation seen in vitro. We then examined which JNK isoforms are active in glial tumors by performing two-dimensional electrophoresis. This revealed that the Mr 55,000 isoforms of JNK2 are the principal active JNK isoforms present in tumors. Collectively, these results suggest that these constitutively active JNK isoforms play a significant role in glial tumors. Aside from epidermal growth factor receptor vIII, this is the only other kinase that has been shown to be basally active in glioma. The presence of constitutively active JNK isoforms may have implications for the design of inhibitors of the JNK pathway.

Original languageEnglish
Pages (from-to)250-255
Number of pages6
JournalCancer Research
Volume63
Issue number1
Publication statusPublished - Jan 1 2003
Externally publishedYes

Fingerprint

JNK Mitogen-Activated Protein Kinases
Neuroglia
Protein Isoforms
Neoplasms
Phosphotransferases
Glutathione Transferase
Epidermal Growth Factor Receptor
Glioma
Transfection
Electrophoresis
Carcinogenesis
Cytoplasm
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Tsuiki, H., Tnani, M., Okamoto, I., Kenyon, L. C., Emlet, D. R., Holgado-Madruga, M., ... Wong, A. J. (2003). Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. Cancer Research, 63(1), 250-255.

Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. / Tsuiki, Hiromasa; Tnani, Mehdi; Okamoto, Isamu; Kenyon, Lawrence C.; Emlet, David R.; Holgado-Madruga, Marina; Lanham, Irene S.; Joynes, Christopher J.; Vo, Kim T.; Wong, Albert J.

In: Cancer Research, Vol. 63, No. 1, 01.01.2003, p. 250-255.

Research output: Contribution to journalArticle

Tsuiki, H, Tnani, M, Okamoto, I, Kenyon, LC, Emlet, DR, Holgado-Madruga, M, Lanham, IS, Joynes, CJ, Vo, KT & Wong, AJ 2003, 'Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors', Cancer Research, vol. 63, no. 1, pp. 250-255.
Tsuiki H, Tnani M, Okamoto I, Kenyon LC, Emlet DR, Holgado-Madruga M et al. Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. Cancer Research. 2003 Jan 1;63(1):250-255.
Tsuiki, Hiromasa ; Tnani, Mehdi ; Okamoto, Isamu ; Kenyon, Lawrence C. ; Emlet, David R. ; Holgado-Madruga, Marina ; Lanham, Irene S. ; Joynes, Christopher J. ; Vo, Kim T. ; Wong, Albert J. / Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. In: Cancer Research. 2003 ; Vol. 63, No. 1. pp. 250-255.
@article{0435f0fbba8240c28e6f40aaa561454d,
title = "Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors",
abstract = "The c-Jun NH2-terminal kinases (JNKs) have a role both in promoting apoptosis and tumorigenesis. The JNKs are encoded by three separate genes (JNK1, 2, and 3), which are spliced alternatively to create 10 JNK isoforms that are either Mr 55,000 or 46,000 in size. However, the functional significance and distinct role for each splice variant remains unclear. We have noted previously that 86{\%} of primary human glial tumors show activation of almost exclusively the Mr 55,000 isoforms of JNK. To further study which isoforms are involved, we constructed glutathione S-transferase fusion proteins for all 10 JNK isoforms and examined kinase activity with or without the activating upstream kinase. Surprisingly, five JNK isoforms demonstrate autophosphorylation activity, and in addition, all four JNK2 isoforms (either Mr 55,000 or 46,000) show a high basal level of substrate kinase activity in the absence of the upstream kinase, especially a Mr 55,000 JNK2 isoform. Examination revealed autophosphorylation activity at the T-P-Y motif, which is critical for JNK activation, because a mutant lacking the dual phosphorylation sites did not show autophosphorylation or basal kinase activity. Using green fluorescence protein-JNK expression vectors, transient transfection into U87MG cells demonstrates that although the JNK1 isoforms localize predominantly to the cytoplasm, the JNK2 isoforms localize to the nucleus and are phosphorylated, confirming the constitutive activation seen in vitro. We then examined which JNK isoforms are active in glial tumors by performing two-dimensional electrophoresis. This revealed that the Mr 55,000 isoforms of JNK2 are the principal active JNK isoforms present in tumors. Collectively, these results suggest that these constitutively active JNK isoforms play a significant role in glial tumors. Aside from epidermal growth factor receptor vIII, this is the only other kinase that has been shown to be basally active in glioma. The presence of constitutively active JNK isoforms may have implications for the design of inhibitors of the JNK pathway.",
author = "Hiromasa Tsuiki and Mehdi Tnani and Isamu Okamoto and Kenyon, {Lawrence C.} and Emlet, {David R.} and Marina Holgado-Madruga and Lanham, {Irene S.} and Joynes, {Christopher J.} and Vo, {Kim T.} and Wong, {Albert J.}",
year = "2003",
month = "1",
day = "1",
language = "English",
volume = "63",
pages = "250--255",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors

AU - Tsuiki, Hiromasa

AU - Tnani, Mehdi

AU - Okamoto, Isamu

AU - Kenyon, Lawrence C.

AU - Emlet, David R.

AU - Holgado-Madruga, Marina

AU - Lanham, Irene S.

AU - Joynes, Christopher J.

AU - Vo, Kim T.

AU - Wong, Albert J.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - The c-Jun NH2-terminal kinases (JNKs) have a role both in promoting apoptosis and tumorigenesis. The JNKs are encoded by three separate genes (JNK1, 2, and 3), which are spliced alternatively to create 10 JNK isoforms that are either Mr 55,000 or 46,000 in size. However, the functional significance and distinct role for each splice variant remains unclear. We have noted previously that 86% of primary human glial tumors show activation of almost exclusively the Mr 55,000 isoforms of JNK. To further study which isoforms are involved, we constructed glutathione S-transferase fusion proteins for all 10 JNK isoforms and examined kinase activity with or without the activating upstream kinase. Surprisingly, five JNK isoforms demonstrate autophosphorylation activity, and in addition, all four JNK2 isoforms (either Mr 55,000 or 46,000) show a high basal level of substrate kinase activity in the absence of the upstream kinase, especially a Mr 55,000 JNK2 isoform. Examination revealed autophosphorylation activity at the T-P-Y motif, which is critical for JNK activation, because a mutant lacking the dual phosphorylation sites did not show autophosphorylation or basal kinase activity. Using green fluorescence protein-JNK expression vectors, transient transfection into U87MG cells demonstrates that although the JNK1 isoforms localize predominantly to the cytoplasm, the JNK2 isoforms localize to the nucleus and are phosphorylated, confirming the constitutive activation seen in vitro. We then examined which JNK isoforms are active in glial tumors by performing two-dimensional electrophoresis. This revealed that the Mr 55,000 isoforms of JNK2 are the principal active JNK isoforms present in tumors. Collectively, these results suggest that these constitutively active JNK isoforms play a significant role in glial tumors. Aside from epidermal growth factor receptor vIII, this is the only other kinase that has been shown to be basally active in glioma. The presence of constitutively active JNK isoforms may have implications for the design of inhibitors of the JNK pathway.

AB - The c-Jun NH2-terminal kinases (JNKs) have a role both in promoting apoptosis and tumorigenesis. The JNKs are encoded by three separate genes (JNK1, 2, and 3), which are spliced alternatively to create 10 JNK isoforms that are either Mr 55,000 or 46,000 in size. However, the functional significance and distinct role for each splice variant remains unclear. We have noted previously that 86% of primary human glial tumors show activation of almost exclusively the Mr 55,000 isoforms of JNK. To further study which isoforms are involved, we constructed glutathione S-transferase fusion proteins for all 10 JNK isoforms and examined kinase activity with or without the activating upstream kinase. Surprisingly, five JNK isoforms demonstrate autophosphorylation activity, and in addition, all four JNK2 isoforms (either Mr 55,000 or 46,000) show a high basal level of substrate kinase activity in the absence of the upstream kinase, especially a Mr 55,000 JNK2 isoform. Examination revealed autophosphorylation activity at the T-P-Y motif, which is critical for JNK activation, because a mutant lacking the dual phosphorylation sites did not show autophosphorylation or basal kinase activity. Using green fluorescence protein-JNK expression vectors, transient transfection into U87MG cells demonstrates that although the JNK1 isoforms localize predominantly to the cytoplasm, the JNK2 isoforms localize to the nucleus and are phosphorylated, confirming the constitutive activation seen in vitro. We then examined which JNK isoforms are active in glial tumors by performing two-dimensional electrophoresis. This revealed that the Mr 55,000 isoforms of JNK2 are the principal active JNK isoforms present in tumors. Collectively, these results suggest that these constitutively active JNK isoforms play a significant role in glial tumors. Aside from epidermal growth factor receptor vIII, this is the only other kinase that has been shown to be basally active in glioma. The presence of constitutively active JNK isoforms may have implications for the design of inhibitors of the JNK pathway.

UR - http://www.scopus.com/inward/record.url?scp=0037224587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037224587&partnerID=8YFLogxK

M3 - Article

C2 - 12517805

AN - SCOPUS:0037224587

VL - 63

SP - 250

EP - 255

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 1

ER -